up 269-6 has been researched along with cyclic gmp in 1 studies
| Studies (up 269-6) | Trials (up 269-6) | Recent Studies (post-2010) (up 269-6) | Studies (cyclic gmp) | Trials (cyclic gmp) | Recent Studies (post-2010) (cyclic gmp) |
|---|---|---|---|---|---|
| 15 | 4 | 0 | 22,346 | 333 | 4,062 |
| Protein | Taxonomy | up 269-6 (IC50) | cyclic gmp (IC50) |
|---|---|---|---|
| Phosphodiesterase | Bos taurus (cattle) | 0.1 | |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase B | Homo sapiens (human) | 2.4 | |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase A | Homo sapiens (human) | 2.4 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jugdutt, BI; Menon, V; Xu, Y | 1 |
1 other study(ies) available for up 269-6 and cyclic gmp
| Article | Year |
|---|---|
Cardioprotection after angiotensin II type 1 blockade involves angiotensin II type 2 receptor expression and activation of protein kinase C-epsilon in acutely reperfused myocardial infarction in the dog. Effect of UP269-6 and losartan on AT1 and AT2-recep
Topics: Angiotensin Receptor Antagonists; Animals; Blood Volume; Calcium Channels; Cardiotonic Agents; Cyclic GMP; Dogs; Enzyme Activation; Female; Hemodynamics; Inositol 1,4,5-Trisphosphate Receptors; Isoenzymes; Losartan; Male; Myocardial Infarction; Myocardial Reperfusion; Myocardium; Protein Kinase C; Protein Kinase C-epsilon; Pyrimidines; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Tetrazoles; Time Factors; Ventricular Function, Left | 2000 |